Success Metrics

Clinical Success Rate
84.3%

Based on 43 completed trials

Completion Rate
84%(43/51)
Active Trials
12(17%)
Results Posted
40%(17 trials)
Terminated
8(11%)

Phase Distribution

Ph phase_3
10
14%
Ph early_phase_1
1
1%
Ph phase_2
38
54%
Ph phase_1
19
27%
Ph phase_4
1
1%

Phase Distribution

20

Early Stage

38

Mid Stage

11

Late Stage

Phase Distribution69 total trials
Early Phase 1First-in-human
1(1.4%)
Phase 1Safety & dosage
19(27.5%)
Phase 2Efficacy & side effects
38(55.1%)
Phase 3Large-scale testing
10(14.5%)
Phase 4Post-market surveillance
1(1.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.7%

43 of 52 finished

Non-Completion Rate

17.3%

9 ended early

Currently Active

12

trials recruiting

Total Trials

71

all time

Status Distribution
Active(14)
Completed(43)
Terminated(9)
Other(5)

Detailed Status

Completed43
Recruiting10
Terminated8
unknown4
Not yet recruiting2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
71
Active
12
Success Rate
84.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.4%)
Phase 119 (27.5%)
Phase 238 (55.1%)
Phase 310 (14.5%)
Phase 41 (1.4%)

Trials by Status

not_yet_recruiting23%
withdrawn11%
suspended11%
recruiting1014%
active_not_recruiting23%
terminated811%
completed4361%
unknown46%

Recent Activity

12 active trials
Showing 5 of 71
recruitingphase_2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
recruitingphase_3

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT04293562
recruitingphase_2

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

NCT01409161
active_not_recruitingphase_2

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00658814
not_yet_recruitingphase_2

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)

NCT06917911
View all 71 trials

Clinical Trials (71)

Showing 20 of 71 trialsScroll for more
NCT05564390Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Recruiting
NCT04293562Phase 3

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Recruiting
NCT01409161Phase 2

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Recruiting
NCT00658814Phase 2

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Active Not Recruiting
NCT06917911Phase 2

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)

Not Yet Recruiting
NCT05183035Phase 3

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Recruiting
NCT05955261Phase 2

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Suspended
NCT00801489Phase 2

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recruiting
NCT05558124Phase 1

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

Recruiting
NCT03672539Phase 2

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Active Not Recruiting
NCT04915612Phase 1

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

Completed
NCT03737955Phase 2

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Recruiting
NCT03568994Early Phase 1

Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)

Completed
NCT03589729Phase 2

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Recruiting
NCT03900949Phase 1

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Completed
NCT04070768Phase 1

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Completed
NCT05662904Phase 1

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML

Not Yet Recruiting
NCT04168502Phase 3

Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
NCT04207190Phase 1

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Completed
NCT03904251Phase 1

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
71